If you have been reading about WADA Prohibited List and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
=== Reprocessing === Fission of the nuclear fuel in any reactor unavoidably produces neutron-absorbing fission products. The fertile material from a breeder reactor then needs to be reprocessed to remove those neutron poisons. This step is required to fully utilize the ability to breed as much or more fuel than is consumed. All reprocessing can present a proliferation concern, since it can extract weapons-usable material from spent fuel. The most common reprocessing technique, PUREX, presents a particular concern since it was expressly designed to separate plutonium. Early proposals for the breeder-reactor fuel cycle posed an even greater proliferation concern because they would use PUREX to separate plutonium in a highly attractive isotopic form for use in nuclear weapons. Several countries are developing reprocessing methods that do not separate the plutonium from the other actinides. For instance, the non-water-based pyrometallurgical electrowinning process, when used to reprocess fuel from an integral fast reactor, leaves large amounts of radioactive actinides in the reactor fuel. More conventional water-based reprocessing systems include SANEX, UNEX, DIAMEX, COEX, and TRUEX, and proposals to combine PUREX with those and other co-processes. All these systems have moderately better proliferation resistance than PUREX, though their adoption rate is low. In the thorium cycle, thorium-232 breeds by converting first to protactinium-233, which then decays to uranium-233.
Many AI systems are so complex that their designers cannot explain how they reach their decisions. Particularly with deep neural networks, in which there are many non-linear relationships between inputs and outputs. But some popular explainability techniques exist. It is impossible to be certain that a program is operating correctly if no one knows how exactly it works. There have been many cases where a machine learning program passed rigorous tests, but nevertheless learned something different from what the programmers intended. For example, a system that could identify skin diseases better than medical professionals was found to actually have a strong tendency to classify images with a ruler as "cancerous", because pictures of malignancies typically include a ruler to show the scale. Another machine learning system designed to help effectively allocate medical resources was found to classify patients with asthma as being at "low risk" of dying from pneumonia. Having asthma is actually a severe risk factor, but since the patients having asthma would usually get much more medical care, they were relatively unlikely to die according to the training data. The correlation between asthma and low risk of dying from pneumonia was real, but misleading. People who have been harmed by an algorithm's decision have a right to an explanation. Doctors, for example, are expected to clearly and completely explain to their colleagues the reasoning behind any decision they make.
Agnolín, Bogan & Lucero (2026) consider Balaena pampaea, Notiocetus romerianus and N. platensis to be nomina dubia, interpreting the fossil material of N. platensis as remains of an indeterminate baleen whale, and interpreting fossils of B. pampaea and N. romerianus as remains of an indeterminate balaenid. Lambert et al. (2026) report shark feeding traces on bones of cetacean specimens from the Pliocene Kattendijk Formation (Belgium), including evidence of a bluntnose sixgill shark feeding on a right whale Balaenella brachyrhynus and evidence of Carcharodon plicatilis feeding on a member of the genus Casatia. López-Galán, Ferrón & Botella (2026) study ecomorphological variation of extant and extinct filter-feeding cetaceans, pachycormiform fishes and selachians, interpreting members of the three groups as repeatedly converging toward analogous functional designs, but also interpreting their convergent evolution as influenced by lineage-specific constraints.
Source: US Energy Information Administration 1 peak production already passed in this state 2 Canadian statistics are complicated by the fact it is both an importer and exporter of crude oil, and refines large amounts of oil for the U.S. market. It is the leading source of U.S. imports of oil and products, averaging 2,500,000 bbl/d (400,000 m3/d) in August 2007. Total world production/consumption (as of 2005) is approximately 84 million barrels per day (13,400,000 m3/d).
=== Additional functional domains === Apart from domains directly involved in catalytic activity further functional domains are present in the CK1δ protein. A kinesin homology domain (KHD) as well as a putative dimerization domain (DD) can be found in the kinase domain. While the KHD allows CK1 isoforms to interact with components of the cytoskeleton. the DD is supposed to be involved in regulation of kinase activity (see below). In the C-lobe, furthermore, a nuclear localization signal (NLS) as well as a centrosome localization signal (CLS) can be found. However, the first one is not sufficient to locate CK1δ to the nucleus.
Sources: en.wikipedia.org
== Leaders of Opposition == Official Opposition is a term used to designate the political party which has secured the second largest number of seats in the assembly. In order to get formal recognition, the party must have at least one-sixth of the total number of Members of the House as required under the aforementioned provisions. However, On 16 May 2026, the Assam Legislative Assembly amended its rules to lower the eligibility threshold for the Leader of the Opposition from one-sixth to one-tenth of the total membership. As a result, a party now requires at least 13 MLAs instead of 21 to qualify, enabling the Indian National Congress, despite its reduced strength, to appoint a Leader of the Opposition in the Assembly.
=== Reports === "Combattre les violences faites aux femmes" [Combating violence against women] (in French). Archived from the original on April 23, 2021. "Bilan de l'application des dispositifs promouvant l'égalité professionnelle entre femmes et hommes" [Review of the implementation of measures promoting professional equality between women and men] (in French). Archived from the original on April 23, 2021. "Femmes éloignées du marché du travail" [Women who are distant from the labor market] (in French). Archived from the original on January 28, 2021. "Kit pour agir contre le sexisme" [Kit to take action against sexism] (in French). November 14, 2016. Retrieved May 8, 2025. "Le sexisme dans le monde du travail" [Sexism in the workplace] (PDF). Conseil Supérieur de l'égalité professionnelle (in French). Archived from the original (PDF) on March 31, 2015. "Écart de rémunération entre hommes et femmes en Europe : faits et chiffres" [Gender pay gap in Europe: facts and figures]. Parlement Européen (in French). March 4, 2020. Archived from the original on January 23, 2021.
In February 2023, President Lula said he was planning to visit Angola, Mozambique and South Africa, and that Brazil should "repay its historical, cultural debt with Africa" through strengthening scientific and technological assistance to African nations.
== History == Mesocarb was first described in the scientific literature by 1971. It is said to have been used as a pharmaceutical drug from 1971 until 2008. It was said to have been discontinued by its manufacturer in 2008 for business reasons unrelated to the drug itself.
Sources: en.wikipedia.org
Homologous recombination OB-fold protein is a protein which in humans is encoded by the gene HROB (previously C17orf53). It is involved in the repair of DNA, and is most highly expressed in the digestive system and female reproductive system. Pathogenic variants have been associated with female reproductive system dysfunction, including premature menopause and ovarian dysgenesis. Neighboring genes of HROB are that of RNU6-131, RNA U6 Small Nuclear 131 Pseudogene, and ASB16, Ankyrin Repeat And SOCS Box Containing 16. HROB has been observed to be expressed ubiquitously across almost all tissue types of the body, but with highest expression found in the duodenum and fallopian tubes, while in the brain there was little region specificity. However, inconsistencies between antibody staining and RNA expression make interpretation of these results difficult.
=== Production of other elements === Americium-241 is sometimes used as a starting material for the production of other transuranic elements and transactinides – for example, neutron bombardment of 241Am yields 242Am:
== Drug interactions == Repaglinide is a major substrate of CYP3A4 and should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole. Administration of both repaglinide and one or more of these drugs results in an increase in plasma concentration of repaglinide and may lead to hypoglycemia. Co-administration of repaglinide and clopidogrel (a CYP2C8 inhibitor) may lead to a significant decrease in blood glucose levels due to a drug-drug interaction. In fact, using these drugs together for even one day can cause repaglinide levels to increase over 5-fold...and may lead to significant hypoglycemia. Repaglinide should not be combined with sulfonylurea, because they have the same mechanism of action.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.